SITE005-0045

SITE005 (FRA) › SITE005-0045

SITE005-0045

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2025-10-25

completed

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-09 (study day 69); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 66); relationship: NOT RELATED

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-30 (study day 60); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-22 (study day 52); relationship: RELATED

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-06-21 (study day 51); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-06-03 (study day 33); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.